Cargando…

Impact of corticosteroids in hospitalised COVID-19 patients

BACKGROUND: Corticosteroids are a potential therapeutic agent for patients with COVID-19 pneumonia. The RECOVERY (Randomised Trials in COVID-19 Therapy) trial provided data on the mortality benefits of corticosteroids. The study aimed to determine the association between corticosteroid use on mortal...

Descripción completa

Detalles Bibliográficos
Autores principales: Ho, Kam Sing, Narasimhan, Bharat, Difabrizio, Larry, Rogers, Linda, Bose, Sonali, Li, Li, Chen, Roger, Sheehan, Jacqueline, El-Halabi, Maan Ajwad, Sarosky, Kimberly, Wang, Zichen, Eisenberg, Elliot, Powell, Charles, Steiger, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023732/
https://www.ncbi.nlm.nih.gov/pubmed/33811098
http://dx.doi.org/10.1136/bmjresp-2020-000766
_version_ 1783675169077723136
author Ho, Kam Sing
Narasimhan, Bharat
Difabrizio, Larry
Rogers, Linda
Bose, Sonali
Li, Li
Chen, Roger
Sheehan, Jacqueline
El-Halabi, Maan Ajwad
Sarosky, Kimberly
Wang, Zichen
Eisenberg, Elliot
Powell, Charles
Steiger, David
author_facet Ho, Kam Sing
Narasimhan, Bharat
Difabrizio, Larry
Rogers, Linda
Bose, Sonali
Li, Li
Chen, Roger
Sheehan, Jacqueline
El-Halabi, Maan Ajwad
Sarosky, Kimberly
Wang, Zichen
Eisenberg, Elliot
Powell, Charles
Steiger, David
author_sort Ho, Kam Sing
collection PubMed
description BACKGROUND: Corticosteroids are a potential therapeutic agent for patients with COVID-19 pneumonia. The RECOVERY (Randomised Trials in COVID-19 Therapy) trial provided data on the mortality benefits of corticosteroids. The study aimed to determine the association between corticosteroid use on mortality and infection rates and to define subgroups who may benefit from corticosteroids in a real-world setting. METHODS: Clinical data were extracted that included demographic, laboratory data and details of the therapy, including the administration of corticosteroids, azithromycin, hydroxychloroquine, tocilizumab and anticoagulation. The primary outcome was in-hospital mortality. Secondary outcomes included intensive care unit (ICU) admission and invasive mechanical ventilation. Outcomes were compared in patients who did and did not receive corticosteroids using the multivariate Cox regression model. RESULTS: 4313 patients were hospitalised with COVID-19 during the study period, of whom 1270 died (29.4%). When administered within the first 7 days after admission, corticosteroids were associated with reduced mortality (OR 0.73, 95% CI 0.55 to 0.97, p=0.03) and decreased transfers to the ICU (OR 0.72, 95% CI 0.47 to 1.11, p=0.02). This mortality benefit was particularly impressive in younger patients (<65 years of age), females and those with elevated inflammatory markers, defined as C reactive protein ≥150 mg/L (p≤0.05), interleukin-6 ≥20 pg/mL (p≤0.05) or D-dimer ≥2.0 µg/L (p≤0.05). Therapy was safe with similar rates of bacteraemia and fungaemia in corticosteroid-treated and non-corticosteroid-treated patients. CONCLUSION: In patients hospitalised with COVID-19 pneumonia, corticosteroid use within the first 7 days of admission decreased mortality and ICU admissions with no associated increase in bacteraemia or fungaemia.
format Online
Article
Text
id pubmed-8023732
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80237322021-04-08 Impact of corticosteroids in hospitalised COVID-19 patients Ho, Kam Sing Narasimhan, Bharat Difabrizio, Larry Rogers, Linda Bose, Sonali Li, Li Chen, Roger Sheehan, Jacqueline El-Halabi, Maan Ajwad Sarosky, Kimberly Wang, Zichen Eisenberg, Elliot Powell, Charles Steiger, David BMJ Open Respir Res Respiratory Infection BACKGROUND: Corticosteroids are a potential therapeutic agent for patients with COVID-19 pneumonia. The RECOVERY (Randomised Trials in COVID-19 Therapy) trial provided data on the mortality benefits of corticosteroids. The study aimed to determine the association between corticosteroid use on mortality and infection rates and to define subgroups who may benefit from corticosteroids in a real-world setting. METHODS: Clinical data were extracted that included demographic, laboratory data and details of the therapy, including the administration of corticosteroids, azithromycin, hydroxychloroquine, tocilizumab and anticoagulation. The primary outcome was in-hospital mortality. Secondary outcomes included intensive care unit (ICU) admission and invasive mechanical ventilation. Outcomes were compared in patients who did and did not receive corticosteroids using the multivariate Cox regression model. RESULTS: 4313 patients were hospitalised with COVID-19 during the study period, of whom 1270 died (29.4%). When administered within the first 7 days after admission, corticosteroids were associated with reduced mortality (OR 0.73, 95% CI 0.55 to 0.97, p=0.03) and decreased transfers to the ICU (OR 0.72, 95% CI 0.47 to 1.11, p=0.02). This mortality benefit was particularly impressive in younger patients (<65 years of age), females and those with elevated inflammatory markers, defined as C reactive protein ≥150 mg/L (p≤0.05), interleukin-6 ≥20 pg/mL (p≤0.05) or D-dimer ≥2.0 µg/L (p≤0.05). Therapy was safe with similar rates of bacteraemia and fungaemia in corticosteroid-treated and non-corticosteroid-treated patients. CONCLUSION: In patients hospitalised with COVID-19 pneumonia, corticosteroid use within the first 7 days of admission decreased mortality and ICU admissions with no associated increase in bacteraemia or fungaemia. BMJ Publishing Group 2021-04-02 /pmc/articles/PMC8023732/ /pubmed/33811098 http://dx.doi.org/10.1136/bmjresp-2020-000766 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Respiratory Infection
Ho, Kam Sing
Narasimhan, Bharat
Difabrizio, Larry
Rogers, Linda
Bose, Sonali
Li, Li
Chen, Roger
Sheehan, Jacqueline
El-Halabi, Maan Ajwad
Sarosky, Kimberly
Wang, Zichen
Eisenberg, Elliot
Powell, Charles
Steiger, David
Impact of corticosteroids in hospitalised COVID-19 patients
title Impact of corticosteroids in hospitalised COVID-19 patients
title_full Impact of corticosteroids in hospitalised COVID-19 patients
title_fullStr Impact of corticosteroids in hospitalised COVID-19 patients
title_full_unstemmed Impact of corticosteroids in hospitalised COVID-19 patients
title_short Impact of corticosteroids in hospitalised COVID-19 patients
title_sort impact of corticosteroids in hospitalised covid-19 patients
topic Respiratory Infection
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023732/
https://www.ncbi.nlm.nih.gov/pubmed/33811098
http://dx.doi.org/10.1136/bmjresp-2020-000766
work_keys_str_mv AT hokamsing impactofcorticosteroidsinhospitalisedcovid19patients
AT narasimhanbharat impactofcorticosteroidsinhospitalisedcovid19patients
AT difabriziolarry impactofcorticosteroidsinhospitalisedcovid19patients
AT rogerslinda impactofcorticosteroidsinhospitalisedcovid19patients
AT bosesonali impactofcorticosteroidsinhospitalisedcovid19patients
AT lili impactofcorticosteroidsinhospitalisedcovid19patients
AT chenroger impactofcorticosteroidsinhospitalisedcovid19patients
AT sheehanjacqueline impactofcorticosteroidsinhospitalisedcovid19patients
AT elhalabimaanajwad impactofcorticosteroidsinhospitalisedcovid19patients
AT saroskykimberly impactofcorticosteroidsinhospitalisedcovid19patients
AT wangzichen impactofcorticosteroidsinhospitalisedcovid19patients
AT eisenbergelliot impactofcorticosteroidsinhospitalisedcovid19patients
AT powellcharles impactofcorticosteroidsinhospitalisedcovid19patients
AT steigerdavid impactofcorticosteroidsinhospitalisedcovid19patients